Sign in

Acute myeloid leukaemia: trials that stopped early

Trials on Acute myeloid leukaemia that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.

Stopped early

167 stopped trials give a reason in the registry, latest registry update first. 4 more give no reason and are not listed.

  1. Terminated

    CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    Reason given in the registry

    “Sponsor Decision - Pipeline Reprioritization”

    Quoted unchanged from ClinicalTrials.gov; record updated 11 Jun 2025.

    Ended
    May 2025
    Phase
    Phase 1
    Run by
    Caribou Biosciences, Inc.
    Registry record
    NCT06128044
  2. Withdrawn

    Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy

    Reason given in the registry

    “The project was terminated as the genetic office did not approve it.”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Jun 2025.

    Phase
    Phase 2
    Run by
    Institute of Hematology & Blood Diseases Hospital, China
    Registry record
    NCT06770257
  3. Terminated

    Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy

    Reason given in the registry

    “The number of participants in the study did not meet expectations”

    Quoted unchanged from ClinicalTrials.gov; record updated 30 May 2025.

    Ended
    Mar 2025
    Phase
    Phase 1/2
    Run by
    Institute of Hematology & Blood Diseases Hospital, China
    Registry record
    NCT06449482
  4. Withdrawn

    Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor

    Reason given in the registry

    “cprmc withdrawn”

    Quoted unchanged from ClinicalTrials.gov; record updated 25 May 2025.

    Phase
    Phase 1
    Run by
    City of Hope Medical Center
    Registry record
    NCT06572631
  5. Terminated

    DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

    Reason given in the registry

    “supporting/funding source decided to de-prioritize and stop development of DS-1594”

    Quoted unchanged from ClinicalTrials.gov; record updated 23 May 2025.

    Ended
    Nov 2023
    Phase
    Phase 1/2
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT04752163
  6. Terminated

    A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)

    Reason given in the registry

    “Business Reasons”

    Quoted unchanged from ClinicalTrials.gov; record updated 21 May 2025.

    Ended
    Dec 2023
    Phase
    Phase 1
    Run by
    Merck Sharp & Dohme LLC
    Registry record
    NCT05038800
  7. Terminated

    XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia

    Reason given in the registry

    “Drug expired May 31, 2024.”

    Quoted unchanged from ClinicalTrials.gov; record updated 8 May 2025.

    Ended
    Nov 2024
    Phase
    Phase 1
    Run by
    Ehab L Atallah
    Registry record
    NCT05038644
  8. Terminated

    Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

    Reason given in the registry

    “The study was terminated early due to slow accrual and low level of interest both by the sponsor and by the department”

    Quoted unchanged from ClinicalTrials.gov; record updated 8 May 2025.

    Ended
    Jun 2024
    Phase
    Phase 1/2
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT03576547
  9. Withdrawn

    Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

    Reason given in the registry

    “Study disapproved by internal scientific review committee on re-review; study will no longer move forward”

    Quoted unchanged from ClinicalTrials.gov; record updated 22 Apr 2025.

    Phase
    Phase 2
    Run by
    University of Florida
    Registry record
    NCT05766514
  10. Terminated

    Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia

    Reason given in the registry

    “Despite a recruitment target that was not met, we managed to achieve more than 50% of inclusions and 33% of deaths, enabling us to carry out an initial analysis of the primary endpoint”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Apr 2025.

    Ended
    May 2024
    Phase
    Phase 3
    Run by
    University Hospital, Toulouse
    Registry record
    NCT03765541
  11. Terminated

    Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies

    Reason given in the registry

    “Terminated - alignment of strategic priorities”

    Quoted unchanged from ClinicalTrials.gov; record updated 10 Apr 2025.

    Ended
    Mar 2025
    Phase
    Phase 1
    Run by
    Blueprint Medicines Corporation
    Registry record
    NCT05609942
  12. Terminated

    Investigating Integrative Therapies for Symptom Management in Adults With Acute Leukemia

    Reason given in the registry

    “The PIs left the institution.”

    Quoted unchanged from ClinicalTrials.gov; record updated 7 Apr 2025.

    Ended
    Mar 2025
    Run by
    University of Florida
    Registry record
    NCT04185428
  13. Terminated

    Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101)

    Reason given in the registry

    “Interim analysis determined that study reached a safety stopping rule”

    Quoted unchanged from ClinicalTrials.gov; record updated 7 Apr 2025.

    Ended
    May 2024
    Phase
    Phase 3
    Run by
    University of Florida
    Registry record
    NCT03016130
  14. Terminated

    Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

    Reason given in the registry

    “Low accrual”

    Quoted unchanged from ClinicalTrials.gov; record updated 6 Apr 2025.

    Ended
    Mar 2024
    Phase
    Phase 2
    Run by
    Memorial Sloan Kettering Cancer Center
    Registry record
    NCT03615105
  15. Terminated

    Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

    Reason given in the registry

    “Study was terminated due to futility”

    Quoted unchanged from ClinicalTrials.gov; record updated 4 Apr 2025.

    Ended
    Apr 2024
    Phase
    Phase 3
    Run by
    Gilead Sciences
    Registry record
    NCT05079230
  16. Terminated

    A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS

    Reason given in the registry

    “The protocol was terminated on the basis of a reprioritization of organizational allocation of resources for clinical research programs.”

    Quoted unchanged from ClinicalTrials.gov; record updated 25 Mar 2025.

    Ended
    Mar 2024
    Phase
    Phase 1
    Run by
    GlaxoSmithKline
    Registry record
    NCT05424380
  17. Withdrawn

    DEC-C and Thioguanine for R/R AML

    Reason given in the registry

    “Difficultly enrolling”

    Quoted unchanged from ClinicalTrials.gov; record updated 24 Mar 2025.

    Ended
    Apr 2024
    Phase
    Phase 2
    Run by
    Columbia University
    Registry record
    NCT06351306
  18. Withdrawn

    A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia

    Reason given in the registry

    “PI Request”

    Quoted unchanged from ClinicalTrials.gov; record updated 12 Mar 2025.

    Ended
    Mar 2025
    Phase
    Phase 1/2
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT06113289
  19. Terminated

    A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

    Reason given in the registry

    “Change in corporate strategy”

    Quoted unchanged from ClinicalTrials.gov; record updated 7 Mar 2025.

    Ended
    Apr 2024
    Phase
    Phase 1
    Run by
    Aptose Biosciences Inc.
    Registry record
    NCT04477291
  20. Terminated

    Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

    Reason given in the registry

    “Strategic considerations”

    Quoted unchanged from ClinicalTrials.gov; record updated 6 Mar 2025.

    Ended
    Feb 2025
    Phase
    Phase 1
    Run by
    AbbVie
    Registry record
    NCT06068868
  21. Terminated

    Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML

    Reason given in the registry

    “Collaborator's decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 26 Feb 2025.

    Ended
    Jul 2024
    Phase
    Early phase 1
    Run by
    920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
    Registry record
    NCT06110208
  22. Terminated

    Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia

    Reason given in the registry

    “didn't reach the primary endpoint”

    Quoted unchanged from ClinicalTrials.gov; record updated 25 Feb 2025.

    Ended
    Dec 2024
    Phase
    Phase 2
    Run by
    Niguarda Hospital
    Registry record
    NCT03686345
  23. Terminated

    Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]

    Reason given in the registry

    “low recruitment rate”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 Feb 2025.

    Ended
    Feb 2025
    Phase
    Phase 1/2
    Run by
    Centre Leon Berard
    Registry record
    NCT06150040
  24. Terminated

    Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

    Reason given in the registry

    “Study discontinued due to futility.”

    Quoted unchanged from ClinicalTrials.gov; record updated 5 Feb 2025.

    Ended
    Mar 2024
    Phase
    Phase 3
    Run by
    Gilead Sciences
    Registry record
    NCT04778397
  25. Terminated

    Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia

    Reason given in the registry

    “poor enrollment”

    Quoted unchanged from ClinicalTrials.gov; record updated 30 Jan 2025.

    Ended
    Jan 2024
    Phase
    Phase 2
    Run by
    Gruppo Italiano Malattie EMatologiche dell'Adulto
    Registry record
    NCT04342962
  26. Withdrawn

    Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host Disease

    Reason given in the registry

    “Kits were not available due to lack of sponsorship”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 Jan 2025.

    Ended
    Nov 2024
    Run by
    Ugur Arzu Kulu
    Registry record
    NCT06200441
  27. Terminated

    Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission

    Reason given in the registry

    “PI decision to close study early due to limited data due to accrual goal not being met”

    Quoted unchanged from ClinicalTrials.gov; record updated 16 Jan 2025.

    Ended
    Aug 2024
    Phase
    Phase 2
    Run by
    University of Florida
    Registry record
    NCT04914676
  28. Terminated

    A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

    Reason given in the registry

    “Study was terminated by the sponsor based on insufficient tolerability and efficacy to proceed beyond Part 1b.”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 Dec 2024.

    Ended
    May 2024
    Phase
    Phase 1/2
    Run by
    Hoffmann-La Roche
    Registry record
    NCT04029688
  29. Terminated

    Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia

    Reason given in the registry

    “Administratively Complete”

    Quoted unchanged from ClinicalTrials.gov; record updated 12 Dec 2024.

    Ended
    Nov 2024
    Phase
    Phase 1
    Run by
    M.D. Anderson Cancer Center
    Registry record
    NCT04526795
  30. Terminated

    A Study of TAS1440 With ATRA in Subjects With r/r AML

    Reason given in the registry

    “The study was terminated due to the changing treatment landscape, difficulty in enrolling eligible participants, and little likelihood of providing meaningful clinical benefit for the participants.”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Dec 2024.

    Ended
    Feb 2024
    Phase
    Phase 1
    Run by
    Taiho Oncology, Inc.
    Registry record
    NCT04282668

Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.